x
Filter:
Filters applied
- CJCA - COVID-19
- Cowan, SimoneRemove Cowan, Simone filter
- Fordyce, Christopher BRemove Fordyce, Christopher B filter
- Sapp, JohnRemove Sapp, John filter
Publication Date
Please choose a date range between 2020 and 2020.
Author
- Bewick, David2
- Chow, Chi-Ming2
- Clarke, Brian2
- Fournier, Anne2
- Gin, Kenneth2
- Gupta, Anil2
- Hardiman, Sean2
- Jackson, Simon2
- Lau, Benny2
- Leong-Poi, Howard2
- Mansour, Samer2
- Marelli, Ariane2
- Roifman, Idan2
- Ruel, Marc2
- Singh, Gurmeet2
- Small, Gary2
- Virani, Sean2
- Wood, David A2
- Zieroth, Shelley2
- Coutinho, Thais1
- Harris, Jennifer1
- Krahn, Andrew1
2 Results
- Training/Practice Contemporary Issues in Cardiology Practice
Cardiac Rehabilitation During the COVID-19 Era: Guidance on Implementing Virtual Care
Canadian Journal of CardiologyVol. 36Issue 8p1317–1321Published online: June 13, 2020- Nathaniel Moulson
- David Bewick
- Tracy Selway
- Jennifer Harris
- Neville Suskin
- Paul Oh
- and others
Cited in Scopus: 39Cardiac rehabilitation programs across Canada have suspended in-person services as a result of large-scale physical distancing recommendations designed to flatten the COVID-19 pandemic curve. Virtual cardiac rehabilitation (VCR) offers an alternate mechanism of care delivery, capable of providing similar patient outcomes and safety profiles compared with centre-based programs. To minimize care gaps, all centres should consider developing and implementing a VCR program. The process of this rapid implementation, however, can be daunting. - Journal News and Commentary
Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence
Canadian Journal of CardiologyVol. 36Issue 8p1180–1182Published online: June 2, 2020- Ricky D. Turgeon
- Shelley Zieroth
- David Bewick
- Chi-Ming Chow
- Brian Clarke
- Simone Cowan
- and others
Cited in Scopus: 3The COVID-19 pandemic invoked the need for prompt guidance and rapid research to address emerging clinical questions. In response to early theoretical concerns regarding the use of renin-angiotensin system (RAS) blockers, including angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), and angiotensin receptor–neprilysin inhibitors (ARNIs) during the COVID-19 pandemic, the Canadian Cardiovascular Society (CCS) and Canadian Heart Failure Society (CHFS) issued guidance to continue these therapies among patients with heart failure and hypertension.